Exopolysaccharide from Lactobacillus rhamnosus KL37 Inhibits T Cell-dependent Immune Response in Mice.
Animals
Anti-Inflammatory Agents
/ metabolism
Arthritis
/ immunology
Arthritis, Experimental
/ immunology
Autoantibodies
/ metabolism
Cell Proliferation
Cells, Cultured
Disease Models, Animal
Humans
Immunity, Humoral
Immunosuppression Therapy
Interferon-gamma
/ metabolism
Lacticaseibacillus rhamnosus
/ physiology
Lymphocyte Activation
Mice
Mice, Inbred DBA
Polysaccharides, Bacterial
/ metabolism
T-Lymphocytes
/ immunology
Collagen-induced arthritis
Exopolysaccharide
Immunomodulation
Inflammation
Lactobacillus rhamnosus
T cells
Journal
Archivum immunologiae et therapiae experimentalis
ISSN: 1661-4917
Titre abrégé: Arch Immunol Ther Exp (Warsz)
Pays: Switzerland
ID NLM: 0114365
Informations de publication
Date de publication:
25 May 2020
25 May 2020
Historique:
received:
19
09
2019
accepted:
10
05
2020
entrez:
26
5
2020
pubmed:
26
5
2020
medline:
20
1
2021
Statut:
epublish
Résumé
Exopolysaccharides (EPSs), major components of the bacterial biofilm, display strong strain-specific immunomodulatory properties. Previously, we have shown that crude EPS derived from Lactobacillus rhamnosus KL37 depresses the production of arthritogenic anti-collagen IgG and ameliorates collagen-induced arthritis (CIA) in DBA/1 mice, when lipopolysaccharide (LPS) was used as adjuvant. In this study, we used highly purified EPS from L. rhamnosus KL37 (EPS-37) to verify its anti-inflammatory properties and the ability to suppress T cell-dependent humoral response. We have employed the model of active CIA, in which mice immunized with type II collagen (CII) along with LPS were treated with pure EPS-37. Intravenous administration of purified EPS-37 markedly ameliorated arthritis and reduced CII-specific antibody production. EPS-37 injected subcutaneously reduced the clinical symptoms of CIA but without the reduction of arthritogenic antibodies. In addition, the effect of EPS-37 on T-cell functions was tested ex vivo and in vitro. EPS-37 inhibited the in vitro proliferation of T cells activated both in vivo (CII immunization) and in vitro (antigen/mitogen), and markedly reduced the production of interferon (IFN)-γ. These results together with other reports suggest that anti-inflammatory potential of EPS-37 depends on its ability to inhibit either one or the other or both possible inflammatory signaling pathways. Namely, Th1 → IFN-γ → M1 inflammatory macrophages → arthritis and/or Th1 → IFN-γ → B cells → arthritogenic antibodies → arthritis. We suggest that L. rhamnosus KL37 EPS might be utilized to control T cell-dependent immune responses in various inflammatory diseases. However, the most effective route of EPS-37 administration needs to be tailored for a given disorder.
Identifiants
pubmed: 32448979
doi: 10.1007/s00005-020-00581-7
pii: 10.1007/s00005-020-00581-7
pmc: PMC7246254
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Autoantibodies
0
Polysaccharides, Bacterial
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Subventions
Organisme : Uniwersytet Jagielloński Collegium Medicum
ID : K/ZDS/000678
Organisme : Ministerstwo Nauki i Szkolnictwa Wyższego
ID : N N401042438
Références
J Biol Chem. 2016 Jun 10;291(24):12538-46
pubmed: 27129225
Int J Exp Pathol. 2011 Dec;92(6):382-91
pubmed: 21950581
Sci Rep. 2018 Jan 29;8(1):1785
pubmed: 29379071
Arthritis Rheumatol. 2014 Oct;66(10):2728-38
pubmed: 24965881
World J Gastroenterol. 2018 Nov 7;24(41):4652-4662
pubmed: 30416313
Springer Semin Immunopathol. 2003 Aug;25(1):3-18
pubmed: 12904888
Int Immunopharmacol. 2009 Jan;9(1):127-33
pubmed: 19013542
Benef Microbes. 2018 Sep 18;9(5):761-773
pubmed: 29726281
Dig Dis Sci. 2011 Mar;56(3):707-14
pubmed: 20683661
Front Immunol. 2014 Jan 14;4:512
pubmed: 24459463
FEMS Microbiol Lett. 2017 Jul 6;364(13):
pubmed: 28605431
J Immunol. 1982 Jan;128(1):337-42
pubmed: 6459373
Arthritis Rheumatol. 2014 Sep;66(9):2368-79
pubmed: 24838610
Carbohydr Res. 2003 Mar 28;338(7):605-9
pubmed: 12644373
Anaerobe. 2019 Apr;56:98-101
pubmed: 30794874
Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):211-20
pubmed: 22484803
J Immunol. 2011 Jun 1;186(11):6585-96
pubmed: 21525381
Curr Pharm Biotechnol. 2017;18(11):883-889
pubmed: 29278212
Biomed Res Int. 2014;2014:106290
pubmed: 24971309
J Appl Microbiol. 2016 Aug;121(2):309-19
pubmed: 26811181
Amino Acids. 2002;23(4):419-26
pubmed: 12436210
Int J Exp Pathol. 2007 Jun;88(3):155-64
pubmed: 17504445
Infect Immun. 2018 Dec 19;87(1):
pubmed: 30396894
Int J Food Microbiol. 2010 Nov 15;144(1):104-10
pubmed: 20884069
Sci Rep. 2016 Oct 06;6:34561
pubmed: 27708357
Microorganisms. 2016 Aug 15;4(3):
pubmed: 27681921
Microbiol Immunol. 2013 Jun;57(6):445-54
pubmed: 23773023
Inflammation. 2016 Oct;39(5):1624-34
pubmed: 27438468
Front Microbiol. 2018 Oct 11;9:2426
pubmed: 30364185
J Exp Med. 2001 Feb 5;193(3):393-7
pubmed: 11157059
J Immunol. 2014 May 15;192(10):4813-20
pubmed: 24740503
J Agric Food Chem. 2015 Aug 12;63(31):7009-15
pubmed: 26207929
Lab Med. 2015 Fall;46(4):277-84
pubmed: 26489671
PLoS One. 2015 Apr 07;10(4):e0123293
pubmed: 25849867
BMC Microbiol. 2011 Aug 03;11:177
pubmed: 21813005
Sci Rep. 2016 Nov 21;6:37613
pubmed: 27869188
J Immunol. 2005 Dec 1;175(11):7512-8
pubmed: 16301659
J Immunol Res. 2017;2017:7416792
pubmed: 28706956
Carbohydr Res. 2010 Jan 11;345(1):108-14
pubmed: 19897181
Arthritis Res Ther. 2014 Apr 16;16(2):R96
pubmed: 24742125
J Immunol. 2017 Apr 1;198(7):2689-2698
pubmed: 28202619
PLoS One. 2017 Jul 6;12(7):e0180025
pubmed: 28683149
Int Immunopharmacol. 2008 Apr;8(4):574-80
pubmed: 18328449
Inflammation. 2017 Oct;40(5):1761-1772
pubmed: 28756520
J Bone Miner Res. 2017 Jul;32(7):1469-1480
pubmed: 28256007
J Bacteriol. 2007 Nov;189(22):7945-7
pubmed: 17675377